GSBS Inhibitors
GSBS inhibitors represent a class of compounds characterized by their ability to impede the activity of specific biochemical pathways through the targeted inhibition of a critical enzyme or signaling molecule, referred to here as GSBS. These inhibitors are fine-tuned to interact with the active site or allosteric sites of GSBS, leading to a change in its conformation and subsequently, its activity. The inhibition process is highly specific, as these molecules are designed based on the intricate understanding of GSBS's structure and the key amino acid residues that are essential for its function. By binding to these strategic sites, GSBS inhibitors effectively block the catalytic activity of the enzyme, which is often a pivotal player in a particular biochemical cascade. This blockade can result in the attenuation of the downstream signaling events that GSBS typically mediates.
The meticulous design of GSBS inhibitors ensures that they have high affinity and selectivity, minimizing off-target effects that could arise from interaction with other proteins. The specificity of these inhibitors is paramount, as it allows for the precise modulation of the biochemical pathway in which GSBS is involved without altering the function of other enzymes or receptors that might have similar structures. The action of GSBS inhibitors can result in the modulation of the production of certain metabolites or the alteration of specific cellular responses that are normally regulated by the GSBS enzyme. The significance of GSBS inhibitors lies in their capacity to influence the pathway in question by hindering the GSBS's activity, which can lead to a decrease in the function or expression of certain proteins downstream in the signaling cascade, providing a controlled approach to study the biochemical pathways in a laboratory setting.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, including protein kinase C (PKC). GSBS activity is dependent on phosphorylation events facilitated by PKC, and inhibition of PKC by Staurosporine would lead to reduced GSBS activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of PI3K. GSBS signaling is modulated partly through the PI3K/AKT pathway. Inhibition of PI3K would diminish AKT activation, indirectly decreasing GSBS activity which is promoted by AKT. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, which is a downstream target of PI3K. By inhibiting mTOR, Rapamycin can indirectly decrease the activity of GSBS, which is enhanced by the mTOR signaling pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which is part of the MAPK/ERK pathway. GSBS is a downstream effector in the MAPK/ERK pathway, and its activity is reduced when MEK is inhibited. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK. GSBS has been found to be activated by p38 MAPK, and inhibition of this kinase by SB203580 would lead to decreased GSBS activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2, which are involved in the MAPK/ERK signaling pathway. GSBS activity is known to be modulated by this pathway, so inhibition by U0126 would reduce GSBS activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a strong inhibitor of PI3K, similar in effect to LY294002. Inhibition of PI3K and subsequent downregulation of AKT would result in decreased activation of GSBS. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which can influence the activity of GSBS through stress-activated signaling pathways. GSBS activity is altered when JNK is inhibited, leading to reduced functional activity of GSBS. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is an AKT inhibitor that prevents its phosphorylation and activation. Since GSBS signaling is partly regulated by AKT, inhibition by Triciribine would lead to a decrease in GSBS activity. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is a potent inhibitor of both mTORC1 and mTORC2, which are part of the mTOR pathway. Since GSBS activity can be modulated by mTOR signaling, inhibition by AZD8055 would decrease its activity. | ||||||